With deeps links to the US likely severed, and HSBC’s risk appetite unknown, what does a future without Silicon Valley Bank look like?
Hopes are high that a buyer will emerge, but the fast-moving downfall of a big name in biopharma banking is not over yet.
Neither route to the stock market covered itself in glory in the recent bull market. But how do returns really stack up?
As Apexigen throws in the towel six months after listing, can any bright spots be found in the stats on Spacs?